About Durata Therapeutics
Durata Therapeutics is a Healthcare company based in Chicago (United States) founded in 2009, and was acquired by Actavis in October 2014. Novel antibiotics for infectious diseases are developed by the company. Durata Therapeutics has completed 1 acquisition, including Vicuron Pharmaceuticals. The company was acqui-hired. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include Insmed, Affinivax and Lodo Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Durata Therapeutics was established in 2009 in Chicago, United States, as a clinical-stage pharmaceutical company. Focus is placed on addressing infectious diseases through the advancement of treatments. Operations center on the late-stage development of dalbavancin, an intravenous antibiotic intended for acute bacterial skin and skin structure infections in hospital and outpatient environments. The domain duratatherapeutics.com is utilized for online presence.
- Headquarters Chicago, United States
- Stage Public
- SectorsHealthcare
- Website duratatherapeutics.com
- Social LinkedIn
- Acquired by Actavis (Oct 2014)
Funding Insights of Durata Therapeutics
- Total Rounds 1
- Last Round Debt – Venture — $25M
- First Round $25M
(Nov 2013)
- Investors Count 1
All 1 funding rounds of Durata Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2013 | $25M | Debt – Venture | – | – |
2 investors in total: 2 institutional.
Investors in Durata Therapeutics
Durata Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Actavis and PDL BioPharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical company undergoing dissolution and asset distribution processes. | pdl.com | |||
Manufacturer of generic products | 1956 | actavis.com | Parsippany Troy Hills, United States |
Investor details for Durata Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Durata Therapeutics
Durata Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Vicuron Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Anti-infectives for hospital-based and community-acquired infections | vicuron.com | King Of Prussia, United States | 1995 | Dec 2009 | •••• |
Complete acquisition details for Durata Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Durata Therapeutics
5 dated milestones of Durata Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Durata Therapeutics is founded.
- Acquisition Acquires Vicuron Pharmaceuticals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $25.0M.
- Exit Acquired by Actavis.
Competitors of Durata Therapeutics
Durata Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Insmed, Affinivax and Lodo Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI |
Detailed competitors of Durata Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Durata Therapeutics
Websites that share an audience with Durata Therapeutics (duratatherapeutics.com).
Websites whose visitors overlap most with Durata Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| themedicinescompany.com | 34% | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as Durata Therapeutics (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Durata Therapeutics
Durata Therapeutics was founded in 2009 and raised its 1st funding round 4 years after it was founded.
Durata Therapeutics is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Durata Therapeutics was established in 2009 in Chicago, United States, as a clinical-stage pharmaceutical company. Focus is placed on addressing infectious diseases through the advancement of treatments. Operations center on the late-stage development of dalbavancin, an intravenous antibiotic intended for acute bacterial skin and skin structure infections in hospital and outpatient environments. The domain duratatherapeutics.com is utilized for online presence.
Durata Therapeutics's top competitors include Insmed, Affinivax and Lodo Therapeutics.
Durata Therapeutics has made 1 acquisition, including Vicuron Pharmaceuticals.
Durata Therapeutics has 2 investors. Key investors include Actavis, and PDL BioPharma.
Yes. Durata Therapeutics was acquired by Actavis in October 2014.